Lonza Group Management

Management criteria checks 4/4

Lonza Group's CEO is Albert Baehny, appointed in Oct 2023, has a tenure of less than a year. directly owns 0.008% of the company’s shares, worth CHF2.93M. The average tenure of the management team and the board of directors is 2.1 years and 6.5 years respectively.

Key information

Albert Baehny

Chief executive officer

CHF784.4k

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	0.008%
Management average tenure	2.1yrs
Board average tenure	6.5yrs

Recent management updates

Recent updates

CEO

Albert Baehny (71 yo)

less than a year

Tenure

CHF784,369

Compensation

Mr. Albert M. Baehny has been Vice Chairman of Investis Holding SA. Mr. Baehny serves as Interim Chief Executive Office of Lonza Group AG since October 01, 2023 and had served as its Interim Chief Executiv...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Albert Baehny	Interim CEO & Chairman	less than a year	CHF784.37k	0.0078% CHF 2.9m
Philippe Deecke	Chief Financial Officer	2.4yrs	no data	0.0032% CHF 1.2m
Maria Nunez	Head of Group Operations	1.8yrs	no data	0.00019% CHF 71.3k
Dirk Oehlers	Vice President of Investor Relations	no data	no data	no data
Andreas Bohrer	Group General Counsel & Company Secretary	no data	no data	no data
Kim Harrelson	Head of Ethics & Compliance	no data	no data	no data
Victoria Morgan	Head of External Communications	no data	no data	no data
Jennifer Clancy	Senior Director of Global Marketing	6.1yrs	no data	no data
Ulrike Kaeppler	Chief Human Resources Officer	less than a year	no data	no data
Matthias Hofmann	Head of Corporate Environment	no data	no data	no data
Jean-Christophe Hyvert	President of Biologics Division	3.3yrs	no data	0.0029% CHF 1.1m
Aurelie Dalbiez	Head of Strategic HR Projects	no data	no data	no data

2.1yrs

Average Tenure

51yo

Average Age

Experienced Management: 0QNO's management team is considered experienced (2.1 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Albert Baehny	Interim CEO & Chairman	7.1yrs	CHF784.37k	0.0078% CHF 2.9m
Barbara Richmond	Independent Non-Executive Director	10.1yrs	CHF316.30k	0.0058% CHF 2.2m
Christoph Mader	Independent Vice Chairman & Lead Independent Director	8.1yrs	CHF334.77k	0.0060% CHF 2.2m
Jurgen Steinemann	Independent Director	10.1yrs	CHF239.33k	0.013% CHF 4.8m
Roger Nitsch	Independent Director	2yrs	CHF251.00k	0.00051% CHF 191.3k
Marion Helmes	Independent Director	2yrs	CHF239.33k	0.00051% CHF 191.3k
Angelica Kohlmann	Independent Director	6yrs	CHF334.77k	0.0023% CHF 855.3k
Olivier Verscheure	Independent Director	6yrs	CHF251.00k	0.0021% CHF 787.8k

6.5yrs

Average Tenure

63yo

Average Age

Experienced Board: 0QNO's board of directors are considered experienced (6.5 years average tenure).

Lonza Group Management

Management criteria checks 4/4

Key information

Recent management updates

Lonza Group AG Announces Chief Executive Officer Changes

Lonza Group AG, Annual General Meeting, May 08, 2024

Lonza Group AG Announces CEO Changes

Lonza Group AG, Annual General Meeting, May 05, 2023

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from November 1, 2022

Lonza Group Announces Management Changes, Effective August 1, 2022

Recent updates

Now 20% undervalued

Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022)

Dividend of CHF2.00 announced

New minor risk - Earnings quality

Lonza Group AG Announces Chief Executive Officer Changes

Lonza Group AG to Report First Half, 2024 Results on Jul 25, 2024

Full year 2023 earnings released: EPS: CHF8.88 (vs CHF16.37 in FY 2022)

Lonza Group AG to Report Fiscal Year 2023 Results on Jan 26, 2024

Lonza Group AG, Annual General Meeting, May 08, 2024

Investor sentiment deteriorates as stock falls 21%

Lonza Group AG Provides Sales Guidance for the Year 2023

Lonza Group AG Announces CEO Changes

First half 2023 earnings released: EPS: CHF5.54 (vs CHF6.67 in 1H 2022)

Lonza Group AG (SWX:LONN) acquired Synaffix BV.

Lonza Group AG (SWX:LONN) acquired Synaffix BV.

Lonza Group AG Reiterates Sales Guidance for the Years 2023

Upcoming dividend of CHF3.50 per share at 0.6% yield

Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021)

Lonza Group AG to Report First Half, 2023 Results on Jul 21, 2023

Full year 2022 earnings released: EPS: CHF16.37 (vs CHF9.08 in FY 2021)

Lonza Group AG Provides Earnings Guidance for the Year 2023

Lonza Group AG (SWX:LONN) announces an Equity Buyback for CHF 2,000 million worth of its shares.

Lonza Group AG, Annual General Meeting, May 05, 2023

Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from November 1, 2022

First half 2022 earnings released

Lonza Group AG Reconfirms Sales Guidance for the Years 2022 and 2024

Lonza Group Announces Management Changes, Effective August 1, 2022

Upcoming dividend of CHF3.00 per share

Insufficient new directors

Sigma-Aldrich Corporation acquired Modular Automated Sampling Technology Platform of Lonza Group AG.

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Lonza Group Ltd. Announces Sales Guidance for the Full-Year 2022

Insufficient new directors

Lonza and Triumvira Immunologics Announces First Patient with HER2-overexpressing Cancer Dosed with TAC-T Cell Therapy Using the Lonza Cocoon Platform

Lonza Group Ltd Provides Earnings Guidance for the Year 2021

First half 2021 earnings released: EPS CHF3.51 (vs CHF5.94 in 1H 2020)

Lonza Group Ltd Approves Dividend, Payable Starting from May 12, 2021

Upcoming dividend of CHF3.00 per share

Altimmune, Inc. Expands AdCOVID™ Manufacturing Collaboration with Lonza

New 90-day high: CHF609

NextPharma Technologies Holding Limited signed an agreement to acquire Lonza's Ploermel (FR) and Edinburgh (UK) sites from Lonza Group Ltd (SWX:LONN).

Capricor Collaborates with Lonza for the Development of Cap-1002, Its Cell Therapy Candidate for the Treatment of Duchenne Muscular Dystrophy and Other Indications

Arbor Biotechnologies and Lonza Enter into Gene Editing Technology Licensing Deal

Aurinia Pharmaceuticals Inc. and Lonza Group Ltd Announce Exclusive Agreement for Dedicated Voclosporin Manufacturing Capacity

Lonza Announces Customer-Dedicated Suites for Commercialization of Bioconjugates

Lonza and Be The Match BioTherapies Partner to Expand Vein-to-Vein Cell and Gene Therapy Supply Chain Network

Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19

New 90-day high: CHF624

Lonza Group Ltd Announces Management Changes

New 90-day high: CHF597

Lonza Reportedly Starts Disposal of Specialty Ingredients Unit

New 90-day high - CHF579

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age